La bourse est fermée

Nicox S.A. (COX.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
4,2100-0,1250 (-2,88 %)
À la clôture : 5:35PM CET
Plein écran
Clôture précédente4,3350
Ouverture4,3000
Offre0,0000 x 0
Vente0,0000 x 0
Var. jour4,1350 - 4,3300
Sur 52 semaines2,5300 - 6,2700
Volume391 420
Volume moyen281 197
Cap. boursière156,208M
Bêta (mensuel sur 5 ans)1,48
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)S.O.
Date de bénéficesS.O.
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividendeS.O.
Objectif sur 1 anS.O.
  • Globe Newswire

    Number of voting rights as of March 5, 2021

    Nicox SASociété anonyme with a registered capital of € 37,103,985 Head Office:DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On March 5, 2021, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of March 5, 2021Total number of shares composing the share capital37,103,985Total number of voting rights37,103,985Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights37,103,985 ---------------www.nicox.comPhone: +33 4-97-24-53-00Fax : +33 4-97-24-53-99 Attachment 5 mars 21 EN

  • Globe Newswire

    Nicox: 2021 Extraordinary and Ordinary Shareholder Meetings

    Press ReleaseNicox: 2021 Extraordinary and Ordinary Shareholder Meetings March 5, 2021Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, has convened an ordinary followed by an extraordinary shareholder meeting on Wednesday April 14, 2021 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France. The documents mentioned in articles R.22-10-23 of the French Code de commerce, including a proxy voting form, will be sent to the shareholders upon written request. These documents will also be made available to shareholders at the headquarters of the Company and on its website http://www.nicox.com by March 24, 2021. Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, will be posted on Nicox’s website by March 24, 2021. Shareholders may also contact the Company’s Investor Relations team at age2021nicox@nicox.com for any question on the voting process. In the event the quorum is not reached on first call, Nicox will convene a shareholder meeting on a second call on Wednesday April 28, 2021 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France. About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage Bryan, Garnier & Co Victor Floc’h Paris, FranceCantor Fitzgerald Louise Chen New York, U.S.Edison Investment Research Pooya Hemami London, UKH.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Damien Choplain Paris, France The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853mchang@lifesciadvisors.comMediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 sophie@lifesciadvisors.comForward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 which are available on Nicox’s website (www.nicox.com).Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Attachment EN_AG 2021- avis de reunion - 5 mars 2021_F

  • Globe Newswire

    Nombre de droits de vote au 5 mars 2021

    Nicox SA Société anonyme au capital de 37 103 985 euros Siège social :DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 5 mars 2021, PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE (Article L.233-8 II du Code de Commerce et les Articles 221-1 et 223-16 du Règlement général de l’AMF) Au 5 mars 2021Nombre total d'actions composant le capital37 103 985Nombre total de droits de vote37 103 985Nombre total de droits de vote, calculé sur la base de l’ensemble des actions composant le capital, y compris les actions privées de droits de vote37 103 985 ---------------www.nicox.comTel : 04-97-24-53-00Fax : 04-97-24-53-99 Pièce jointe 5 mars 21 FF